Clinical trials: Esophagus Adenocarcinoma
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006472
- Testing
- carboplatin, fluorouracil, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Medstar Health Research Institute
Esophageal Cancer
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so it can be…
- Trial name
- NCT00047112
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 73 sites in Belgium, France and 2 more
- Volunteers
- 195 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Esophageal Cancer, Gastric Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with surgery is more effective than surgery alone.
- Trial name
- NCT00002883
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- France
- Volunteers
- 250 people
- Sponsor
- UNICANCER
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Esophageal Adenocarcinoma, Gastric Cancer
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment.
- Conditions
- Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CIT-SEQ (NCT07660627)
- Testing
- NGS sequencing of mutations selected based on sequencing of primary tumors
- Where
- Czechia
- Volunteers
- 34 people
- Sponsor
- Masaryk Memorial Cancer Institute
Oesophagus Cancer, Barrett Esophagus
Classification of Adenocarcinoma of the Esophagogastric Junction
The Siewert classification of oesophageal cancer is the standard approach in anatomically subdividing cancer of the lower oesohagus.
- Conditions
- Oesophagus Cancer, Barrett Esophagus, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Trial name
- NCT04151524
- Where
- Ireland
- Volunteers
- 1,658 people
- Sponsor
- St. James's Hospital, Ireland
Esophageal Cancer, Gastric Cancer
Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery
RATIONALE: Drugs used in chemotherapy such as cisplatin and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00011960
- Testing
- cisplatin, paclitaxel, adjuvant therapy
- Where
- 69 sites in United States
- Sponsor
- Radiation Therapy Oncology Group
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Barrett Esophagus, Esophageal Adenocarcinoma
Lucid Registry Study
This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management information on subjects who undergo EC/EG to assess for the presence…
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
- Trial name
- Lucid Registry (NCT05965999)
- Testing
- EsoCheck®, EsoGuard®
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Lucid Diagnostics, Inc.
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Esophageal Cancer
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00004897
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Sponsor
- Northwestern University
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and saliva from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00963092
- Testing
- DNA analysis, RNA analysis, microarray analysis
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Cancer Research UK
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00041262
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United Kingdom
- Volunteers
- 1,300 people
- Sponsor
- Medical Research Council
Esophagus Cancer, Gastric Cancer
HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes
Targeted therapies offer promise to improve oncologic outcomes in esophagogastric adenocarcinoma (EGA). The landmark 'Trastuzumab for gastric cancer (ToGA)' trial established the therapeutic value of Human Epidermal Growth Factor…
- Conditions
- Esophagus Cancer, Gastric Cancer, HER2-positive Cancer, HER2-low Cancer
- Trial name
- HERA (NCT06550063)
- Where
- Ireland
- Volunteers
- 2,188 people
- Sponsor
- St. James's Hospital, Ireland
Barrett Esophagus, Barretts Esophagus With Dysplasia
CLUE: CLinical Utility Study of EsoGuard
Utilize real-world data from the commercial use of EsoGuard testing on samples collected with EsoCheck (EC/EG) to evaluate the impact of EsoGuard results on health care provider's decision for endoscopy referral.
- Conditions
- Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophagus Adenocarcinoma
- Trial name
- PR-0410 (NCT06030180)
- Testing
- EsoGuard
- Where
- 8 sites in United States
- Volunteers
- 566 people
- Sponsor
- Lucid Diagnostics, Inc.
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastric Cardia
Nodal Status in Adenocarcinoma of the Esophagus an Cardia
Adenocarcinoma of the distal esophagus and cardia are grouped among the thoracic tumors according to the TNM 7th ed., however controversy is pending on the unique or dual pathogenesis (GERD or gastric-like cancerogenesis).
- Trial name
- NCT01635595
- Testing
- Subtotal esophagectomy and gastric pull up, Subtotal esophagectomy at the azygos vein, total gastrectomy
- Where
- Italy
- Volunteers
- 194 people
- Sponsor
- University of Bologna
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006038
- Testing
- cisplatin, docetaxel, floxuridine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Oesophageal Adenocarcinoma, T Cells
Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?
Background Regular exercise can significantly improve physical and mental health during cancer treatment and reduce the time needed in the hospital.
- Conditions
- Oesophageal Adenocarcinoma, T Cells, Tumor Microenvironment, Exercise
- Trial name
- OPTIMUS (NCT07375420)
- Testing
- Low intensity exercise, High intensity exercise
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Surrey